Tag Archives: Michael Matson

Analysts’ Top Healthcare Picks: Hologic (HOLX), Precision BioSciences (DTIL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hologic (HOLX – Research Report) and Precision BioSciences (DTIL – Research Report) with bullish sentiments. Hologic (HOLX) Needham analyst Michael Matson reiterated

Boston Scientific (BSX) Gets a Buy Rating from Needham

In a report released today, Michael Matson from Needham maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target of $43.00. The company’s shares closed last Thursday at $30.91. According to TipRanks.com, Matson is a

Needham Sticks to Their Buy Rating for Medtronic (MDT)

In a report issued on March 30, Michael Matson from Needham maintained a Buy rating on Medtronic (MDT – Research Report), with a price target of $109.00. The company’s shares closed last Wednesday at $84.11. According to TipRanks.com, Matson is

Needham Reaffirms Their Buy Rating on Masimo (MASI)

Needham analyst Michael Matson maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $201.00. The company’s shares closed last Wednesday at $181.48, close to its 52-week high of $187.86. According to TipRanks.com,

Needham Reiterates Their Buy Rating on Invacare (IVC)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Invacare (IVC – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $4.33, close to its 52-week low of $3.90.

GenMark (GNMK) Receives a Buy from Needham

Needham analyst Michael Matson reiterated a Buy rating on GenMark (GNMK – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $5.40. According to TipRanks.com, Matson is a 1-star analyst with an